| Nov. 14, 2009 |
Merck Strengthens Its Commitment to Advancing Cardiovascular Health Care |
| Nov. 13, 2009 |
NYT Letter to the Editor from Dr. Richard Pasternak |
| Nov. 04, 2009 |
New Merck Begins Operations |
| Nov. 03, 2009 |
Merck and Schering-Plough to Complete Merger Today |
| Oct. 29, 2009 |
Merck and Schering-Plough Receive Approvals From U.S. Federal Trade Commission, Swiss Competition Commission and Canadian Competition Bureau for Merger |
| Oct. 23, 2009 |
Merck and Schering-Plough Receive Approval From European Commission for Merger |
| Oct. 22, 2009 |
The Supreme Court of Canada Will Not Review the Saskatchewan Court of Appeal Judgment Overturning a Class Certification Order in VIOXX® Action
|
| Oct. 08, 2009 |
300 Doctors at your Fingertips: New Merck Manuals Deliver Convenient and Trusted Medical Information to Consumers |
| Sep. 28, 2009 |
Merck & Co., Inc. Obtains Exclusive U.S. Marketing Rights for AFLURIA®, Seasonal Influenza Vaccine from CSL Biotherapies |
| Sep. 18, 2009 |
Sanofi-aventis Completes Acquisition of Merck's Interest in Merial |
| Sep. 11, 2009 |
Mistrial Declared in First Federal FOSAMAX® Trial |
| Sep. 03, 2009 |
Three Directors Set For Newly-Combined Merck |
| Aug. 31, 2009 |
Merck CEO Announces Structure and Global Leadership Team for New Merck |
| Aug. 19, 2009 |
Merck Wins SINGULAIR® Patent Infringement Lawsuit |
| Aug. 11, 2009 |
Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in U.S. District Court |
| Aug. 07, 2009 |
Merck Shareholders Approve Merger With Schering-Plough |
| Aug. 05, 2009 |
Merck and Schering-Plough Resolve Previously Disclosed Civil Class Action Lawsuits Related to VYTORIN® (ezetimibe/simvastatin) and ZETIA® (ezetimibe) |
| Jul. 30, 2009 |
Sanofi-aventis to Acquire Merck's Interest in Merial |
| Jul. 24, 2009 |
Merck Reports Proposed Settlement of Litigation Involving Planned Merger with Schering-Plough |
| Jul. 15, 2009 |
Merck and Schering-Plough Resolve Previously Disclosed Investigation Under State Consumer Protection Statutes Related to VYTORIN® (ezetimibe/simvastatin) and ZETIA® (ezetimibe) |
| Jun. 22, 2009 |
Merck and Schering-Plough Receive Request for Additional Information from FTC Regarding Proposed Merger |
| Jun. 20, 2009 |
Merck & Co., Inc. Statement on Medicare Part D Assistance |
| May 29, 2009 |
Merck Statement on United States Patent & Trademark Office Decision to Reexamine the SINGULAIR® Patent |
| May 27, 2009 |
Schering-Plough and Merck Provide Update on Distribution Agreement |
| May 13, 2009 |
Merck Statement on Missouri Court of Appeals Decision Affirming a Ruling Certifying a Class of Missouri Plaintiffs Seeking Out-of-Pocket VIOXX® Costs |
| May 11, 2009 |
Ontario Court Grants Merck Time to Appeal Class Certification of Vioxx Action |
| May 11, 2009 |
Merck & Co., Inc. Statement on Health Reform Meeting with President Obama |
| May 08, 2009 |
Merck Statement on California Court Ruling Denying Certification of Class of Plaintiffs Seeking Reimbursement for VIOXX® Costs |
| Apr. 15, 2009 |
Solar Energy Tapped to Power World Headquarters of Merck & Co., Inc. |
| Mar. 30, 2009 |
Court of Appeal for Saskatchewan Allows Merck's Appeal and Overturns Class Certification of Vioxx Action |
| Mar. 23, 2009 |
Merck & Co., Inc. Provides Update on Previously-Disclosed U.S. Department of Justice Investigation Relating to VIOXX® |
| Mar. 23, 2009 |
Merck Provides Update on Merger Financing |
| Mar. 18, 2009 |
Merck & Co., Inc. Donates Antimalarial Candidate to Medicines for Malaria Venture for Use in Developing World |
| Mar. 17, 2009 |
Merck Statement on New Jersey Court Ruling Denying Certification of Class of Plaintiffs Seeking Reimbursement for Out-of-Pocket VIOXX® Costs |
| Mar. 09, 2009 |
MERCK AND SCHERING-PLOUGH TO MERGE |
| Feb. 25, 2009 |
Dr. Thomas Cech Nominated to Join Merck Board of Directors |
| Feb. 17, 2009 |
Carlos E. Represas Elected to Merck Board of Directors |
| Feb. 12, 2009 |
Merck & Co., Inc. Acquires Biologic Manufacturing Capabilities and Developmental Follow-on Biologics Portfolio from Insmed |
| Feb. 02, 2009 |
Dr. D. Gary Gilliland, Internationally-Recognized Physician and Researcher, Joins Merck Research Labs as Head of Oncology Research |
